Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27520483 | 0.88 | CA12 (0.55) | ALDH1A1KDM4EHPGDHSD17B10CYP4F2 | |
| SCHEMBL13566535 | 0.87 | CYP4F2 (0.48) | ALDH1A1KDM4EHPGDHSD17B10POLB | |
| SCHEMBL27507369 | 0.85 | CNR1 (0.47) | ALDH1A1KDM4EHPGDHSD17B10POLB | |
| SCHEMBL23218385 | 0.85 | CA1 (0.49) | ALDH1A1KDM4EHPGDHSD17B10POLB | |
| SCHEMBL27290287 | 0.83 | ALOX5 (0.50) | ALDH1A1POLBCA12CA1CA2 | |
| SCHEMBL8566189 | 0.83 | CNR1 (0.56) | ALDH1A1CYP4F2CYP4A11CA12CA1 | |
| SCHEMBL27545957 | 0.83 | CNR1 (0.56) | ALDH1A1KDM4EHPGDCYP4F2CYP4A11 | |
| SCHEMBL27541491 | 0.82 | LTB4R (0.43) | ALDH1A1KDM4EHPGDHSD17B10POLB | |
| SCHEMBL8569884 | 0.82 | CNR2 (0.54) | CYP4F2CYP4A11CA12CA1CA7 | |
| SCHEMBL27545958 | 0.81 | CNR1 (0.62) | MEN1KMT2ALMNACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1513817-A1 | 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003099793-A1 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-04 | — | — | WO | disclosed |
| EP-0544488-B1 | Substituted phenyl phenol leukotriene antagonists | LILLY CO ELI (US) | 1998-03-11 | — | — | EP | disclosed |
| WO-1996036347-A1 | USE OF LEUKOTRIENE ANTAGONISTS FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0743064-A1 | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease | ELI LILLY AND COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5462954-A | Antiinflammatory, antiallergens; treating asthma | ELI LILLY AND COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0544488-A2 | Substituted phenyl phenol leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | ALDH1A1 1442/4885KDM4E 509/4885HPGD 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.